SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company is featured as a special stock pick in the October 2010 issue of the KonLin Letter, an independent New York-based investment newsletter (www.konlin.com) published by KonLin Research & Analysis. The investment letter highlights Apricus Bio’s proprietary technology and pipeline of 13 clinical and pre-clinical product candidates in various stages of development.
